Red Blood Cell Membrane-derived Microparticles And Their Use For The Treatment Of Lung Disease

  • Published: Jun 26, 2018
  • Earliest Priority: Nov 07 2013
  • Family: 4
  • Cited Works: 19
  • Cited by: 0
  • Cites: 8
  • Additional Info: Cited Works Full text

Cell-based therapies show considerable potential as an immunomodulatory strategy for a variety of lung diseases, including chronic obstructive pulmonary disease (COPD), asthma, bronchiolitis, acute lung injury, lung allograft rejection (acute or chronic), pulmonary fibrosis. Described herein is the development of red blood cell membrane-derived microparticles (RBC MPs), which are depleted of hemoglobin (Hb) and express phosphatidylserine on their surface, for the treatment of lung disease. Administration of RBC MPs to the lung via inhalation promotes the production of immunoregulatory cytokines (such as IL-10), and reduces inflammation and injury in the lung.

Download PDF
Document Preview
Document History
  • Publication: Jun 26, 2018
  • Application: Nov 6, 2014
    US US 201415034700 A
  • Priority: Nov 6, 2014
    US US 201415034700 A
  • Priority: Nov 6, 2014
    US US 2014/0064352 W
  • Priority: Nov 7, 2013
    US US 201361901247 P

Download Citation

Sign in to the Lens